Entera Bio Ltd. (NASDAQ: ENTX) reported 3 months of results on their ongoing Phase 2 clinical trial of EB613, the company’s orally delivered human parathyroid hormone. Positioned to be the first oral bone building product to treat osteoporosis. The phase 2 clinical trial will last a total of 6months in a study that is being conducted in four leading medical centers in Israel to evaluate the safety of EB613 and identify the best dose for potential Phase 3 trial registration.
Shares of Entera Bio rallied to a new 52-week high of USD 6.20 on Thursday with over 150 million shares traded.
“We are very pleased and highly encouraged by the complete 3-month biomarker data from this trial. When taken together with the previously reported interim BMD data, these results support a dose response in BMD. We look forward to reporting the final results, including the 6-month BMD data, from this trial in the second quarter of 2021,” stated Entera CEO Spiros Jamas. “We believe these data support ongoing business development discussions with strategic partners with interests in osteoporosis. We also believe these data and previously reported data illustrate the power of Entera’s drug delivery platform for oral dosing of large biological molecules.